Compound Screening TRIZ Cases

A biotinylated lipid micelle assay detects lipid-modifying enzyme activity using proximity effect-based methods.

A biomarker-based method identifies skin compositions that improve tissue quality through measurable biochemical changes.

Screen mutant EGFr polypeptides to select binding agents with tailored epitope affinity, resolving specificity and efficacy trade-offs in cancer therapy.

Modifying AKG analogue structures reduces cytotoxicity while maintaining demethylase inhibition efficacy for prostate cancer treatment.

An in vitro plasma-substrate system measures lipasaemic activity via optical density changes to evaluate glycosaminoglycan compounds.

An isolated polypeptide inhibits caspase-2-dependent tau cleavage, reducing pathogenic fragments that drive memory loss in tauopathy.

Domain-specific antibodies assess EGFR phosphorylation status to predict patient responses to inhibitor therapies amid heterogeneous tumor populations.

SV40 large T-antigen and hTERT expression immortalizes neuronal cells while preserving biochemical properties.

Segmenting reagents into discrete droplets eliminates diffusion and surface adsorption, enabling reliable enzyme quantification at minute scales.

Targeted inhibitors suppress mutant EZH2 activity to reduce cancer cell proliferation and induce apoptosis in lymphoma.

Peptide inhibitors bind the cyclin D binding groove to selectively constrain CDK4 activity.

Replacing enzymatic digestion with mechanical micro-dissection eliminates contamination risks while ensuring consistent cell population homogeneity.

Open reversed microwell device manages fluids via interference coupling to enable high-content biological sample analysis.

Intestinal epithelial monolayers use biosensors to detect inflammation signals, breaking the chronic positive feedback loop in inflammatory bowel disease.

Genetically modified mice expressing human APOE4 and mouse Trem2 p.R47H proteins enable preclinical screening.

Forward programming pluripotent stem cells with endothelial factor genes bypasses complex multi-stage differentiation protocols.

Stable isotope labeling kinetics quantifies alpha-synuclein metabolism to resolve insufficient protein measurement precision in neurological disease diagnosis.

A 3D printer creates magnified hair surface models from imaging data to visualize treatment effects.

Antibody 7C10-C5 detects carboxymethylated PP2Ac without cross-reactivity, resolving measurement precision issues.

Modified carrier cells express immunosuppressive factors to protect oncolytic viruses from immune elimination and enhance viral amplification at tumor sites.

Polymer-coated nanoparticles target hepatocellular carcinoma cells to enable high-resolution visualization through spatial frequency heterodyne imaging.

Stacking planar conductors on parallel planes with vertical vias increases reactance, enabling lower resonance frequencies and compact device integration.

Mid-sized peptides bind Arid5a RNA-binding domains to block pro-inflammatory cytokine production.

Segmented nucleic acid screening and bioinformatic mediation resolve the contradiction between diagnostic precision and process complexity.

Synthetic fragment antigen-binding antibodies bind the N-terminal activation site of BAX, preventing premature apoptotic cell death.

Mapping specific residues in the HCMV glycoprotein B polypeptide allows precise therapeutic targeting to inhibit viral fusion and prevent infection.

Targeting the T14 peptide via alpha7 nicotinic receptor binding resolves the trade-off between general treatment effectiveness and metastatic specificity.

Pyrazolopyridazine compounds interact with key proteins to address inadequate treatments for retinal degeneration and hearing loss in Usher Syndrome.

HLA expression segmentation isolates cancer stem cells to identify agents that reduce tumor recurrence.

CD31 peptide fragments engage the ITIM pathway to inhibit T-cell activation, addressing ineffective current therapies for thrombotic disorders.

Segmented design enables precise protein regulation via light-induced conformational changes without increasing device complexity.

A recombinant polypeptide links a reporter moiety to a destabilization domain via a cleavage site.

Algorithms identify antibody-binding peptide sequences, replacing complex biological preparations with reproducible synthetic epitopes.

Engineered antibodies bind PSGL-1 to block selectin interactions, resolving the trade-off between therapeutic efficacy and unwanted immune activation.

Universal antidotes bind nucleic acid molecules through electrostatic interactions to reverse pharmacological activity.

Electroporation delivers nucleic acids into mammalian cells to produce recombinant proteins with targeted localization.

Lectin binding assays analyze protein glycosylation profiles to overcome unreliable blood glucose measurements and improve diagnostic precision.

Thickening agent immobilizes cells within a gel matrix for reactive oxygen species detection.

RIC3 chaperone proteins stabilize nematode ACR-16 receptors in mammalian cells to identify novel anthelmintic compounds.

Determines baseline protein expression in circulating tumor cells to predict cancer treatment responsiveness.

HBP polypeptide binds to the FPRL2 receptor to detect polypeptide activity, resolving limited detection capability without increasing system complexity.

Inducing proton leakage through the mitochondrial F1Fo ATP Synthase c-subunit suppresses glioma proliferation in TMZ-resistant cases.

Inhibiting the SUMO conjugation pathway overcomes subtype variability to treat glioblastoma effectively.

Screening methods identify agents modulating adrenergic receptor gene expressions to reduce melanin production in pigmented skin.

Anti-DKK1 antibody targets DKK1 biomarker to simplify diagnosis while suppressing metastasis.